Skip to main content
Abbott India Ltd. logo

Abbott India Ltd. — Investor Relations & Filings

Ticker · ABBOTINDIA ISIN · INE358A01014 LEI · 5493008KZ9E3HFRN6T46 BSE.NS Manufacturing
Open in API
Filings indexed 3 across all filing types
Latest filing 2026-05-11 Notice of Dividend Amou…
Country IN India
Listing BSE.NS ABBOTINDIA

About Abbott India Ltd.

https://www.abbott.co.in

Abbott India Ltd. is a pharmaceutical entity focused on providing high-quality healthcare solutions through a diverse portfolio of trusted brands. The company specializes in several key therapeutic areas, including women's health, gastroenterology, cardiology, metabolic disorders, primary care, and the central nervous system. Its product range features well-known formulations such as Duphaston, Thyronorm, Udiliv, Vertin, and Digene. The organization leverages advanced manufacturing capabilities and an extensive distribution network to serve healthcare professionals and patients. It emphasizes science-based innovation and clinical excellence to address evolving medical needs. By maintaining a strong focus on patient outcomes and therapeutic efficacy, the company has established itself as a reliable provider of pharmaceutical products across various specialized and general medical segments.

Recent filings

Filing Released Lang Actions
Record Date for Dividend
Notice of Dividend Amount Classification · 95% confidence The document is an official notice to the stock exchange under SEBI Listing Regulations informing shareholders of the record date and payment date for the final dividend for the financial year ended March 31, 2026. It details dividend entitlement, record date (July 24, 2026), and payment timing. This matches the criteria for a Notice of Dividend Amount (code DIV).
2026-05-11 English
Audited Financial Results for the quarter and year ended March 31, 2026
Interim / Quarterly Report Classification · 92% confidence The document is a submission under SEBI Regulation 33 disclosing the audited financial results for the quarter and year ended March 31, 2026, including full statements (income, assets & liabilities, cash flows) and notes. This is more than an earnings highlight release and contains substantive financial data for a quarterly/periodic report outside of a full Annual Report. It matches the definition of an Interim / Quarterly Report under category IR, rather than a 10-K or simple earnings release. FY 2026
2026-05-11 English
Outcome of Board Meeting
Earnings Release Classification · 80% confidence The document is an official stock‐exchange filing under SEBI Listing Regulations detailing the ‘Outcome of Board Meeting’, including the Audited Financial Results for the quarter and full year ended March 31, 2026, the Statement of Assets & Liabilities, Cash Flows and dividend recommendation. It is not merely a notice of report publication, but the actual earnings release for the period. This matches the definition of an Earnings Release (initial announcement of periodical financial results). FY 2026
2026-05-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.